Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs Novo Nordisk A/S — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $27.45, while Novo Nordisk A/S trades at $49.35 (market cap $220.53B). The key difference: Novo Nordisk A/S pays a 3.63% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none. Which is the better fit depends on your goals.
| KOLD | NVO | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $71.70 |
52-Week Low | $13.58 | $35.29 |
Market Cap | — | $220.53B |
Enterprise Value | — | $239.49B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD, a natural gas-focused ETF, trades at $28.25, up 4.01% today with strong bullish momentum from moving averages. Technical indicators show overbought conditions with RSI readings above 70, while ADX signals strong trend direction. Recent news highlights natural gas market volatility driven by weather forecasts and storage reports, with the EIA projecting record supply and demand for 2026.
The outlook remains tactical with heightened volatility expected from weather patterns and LNG export flows. Investment opportunities exist for short-term traders using KOLD as a hedging instrument, though overbought technicals and natural gas price sensitivity pose near-term risks. The ETF's performance is directly tied to natural gas futures price movements and market sentiment.
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
